We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NeuroSense Therapeutics continues to report promising trends in their NST002 Phase IIa study, conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC).